the ANRS CO21 " Extreme " Cohort (CODEX)
A consortium of research teams has studied the immunovirological characteristics of these patients: The ANRS CO15 ALT cohort The ANRS CO18 HIV Controller cohort the ANRS EP47 VISCONTI study
| Condition(s) | HIV Infection |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | A consortium of research teams has studied the immunovirological characteristics of these patients: The ANRS CO15 ALT cohort The ANRS CO18 HIV Controller cohort the ANRS EP47 VISCONTI study |
| Who can participate | Inclusion Criteria: * Patient infected with HIV-1 and not co-infected with HIV-2 * Age ≥ 18 at enrollment * Able to give written consent * Covered by French Social Security * accept the constraints imposed by the study * without antiretroviral therapy for ALT, HIC and ALT HIC groups and a control of viral load after antiretroviral treatment interruption in PTC group ALT group: Documented HIV-1 seropositive for at least 8 years with a CD4 count above 600/mm3 with a rate stable or increasing (positive or zero slope) on at least three consecutive examinations performed during the last 5 years regardless of the viral load in the absence of antiretroviral treatment HIC group: HIV-1 Seropositivity known for at least five years, asymptomatic, with the last 5 viral loads in HIV-RNA consecutive \<4 |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Lead sponsor | ANRS, Emerging Infectious Diseases |
| Locations | Le Kremlin-Bicêtre, France |
| Start date | 2012-02 |
| NCT ID | NCT01520844 |
| Official listing | https://clinicaltrials.gov/study/NCT01520844 |